A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Not Recruiting

Trial ID: NCT01306890

Age - 18 Years-N/A Condition - Prostate Cancer Gender - Male Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.

Official Title

A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Eligibility


Inclusion Criteria:

   - subjects must be at least 18 years of age

   - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
   their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
   enrollment

   - subjects must understand and sign an informed consent form

Exclusion Criteria:

   - none

View More
View Less

Intervention(s):

biological: sipuleucel-T

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas
6507361252

New Trial Alerts

©2024 Stanford Medicine